Chronic Kidney Disease Market to Observe Impressive Growth at a CAGR of 8.7% by 2032, Estimates DelveInsight

27 Apr 2023
www.prnewswire.com
Drug Approval
The expected launch of therapies by several pharma companies such as ProKidney, Reata Pharmaceuticals, Inc., Novo Nordisk A/S, Boehringer Ingelheim, Eli Lilly and Company, AstraZeneca, and others will lead to change in the chronic kidney disease market dynamic during the forecast period (2023-2032)
LAS VEGAS, April 27, 2023 /PRNewswire/ -- DelveInsight's
Chronic Kidney Disease Market Insights report includes a comprehensive understanding of current treatment practices, chronic kidney disease emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
Key Takeaways from the Chronic Kidney Disease Market Report
As per DelveInsight analysis, the chronic kidney disease market size in the 7MM was approximately
USD 5 billion in 2022.
According to the assessment done by DelveInsight, the estimated total diagnosed prevalent chronic kidney disease cases in the 7MM were approximately
16 million in 2022.
Leading chronic kidney disease companies such as
The promising chronic kidney disease therapies in the pipeline include
, and others.
Discover which therapies are expected to grab the major chronic kidney disease market share @
Chronic kidney disease occurs when the kidneys get damaged and cannot filter blood as efficiently as they should. Chronic kidney disease is defined as abnormalities in kidney structure or function that have been present for more than three months and have a negative impact on health. Chronic kidney disease is categorized into five phases based on the extent of kidney damage and function. In stage 1, there is modest kidney disease, and in stage 5, the kidneys have stopped working. The severity of chronic kidney disease varies.
In the early stages of kidney disease, there are usually no chronic kidney disease symptoms. It can only be diagnosed if a blood or urine test is performed for another reason and the results show a kidney issue. Tiredness, swollen ankles, feet, or hands, shortness of breath, unwellness, and blood in the urine indicate a more advanced stage. Chronic kidney disease can be detected using blood and urine tests. The eGFR blood test measures the efficiency with which the kidneys function. Ultrasound, CT scan, X-ray, and MRI imaging examinations are also used for chronic kidney disease diagnosis.
Chronic Kidney Disease Epidemiology Segmentation
DelveInsight estimates that there were approximately
16 million diagnosed prevalent cases of chronic kidney disease in the 7MM in 2022.
As per our analysis, chronic kidney disease has been identified as a female-dominant disease, with more females suffering than males. In 2022,
52% of cases of CKD were of females, while
48% of cases were of males in the 7MM.
The
chronic kidney disease market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
Chronic Kidney Disease Prevalent Cases
Chronic Kidney Disease Diagnosed Prevalent Cases
Chronic Kidney Disease Gender-specific Diagnosed Prevalent Cases
Chronic Kidney Disease Age-specific Diagnosed Prevalent cases
Chronic Kidney Disease Complication-specific Diagnosed Prevalent cases
Chronic Kidney Disease Stage-specific Diagnosed Prevalent Cases
Chronic Kidney Disease Etiology-specific Diagnosed Prevalent Cases
Download the report to understand which factors are driving chronic kidney disease epidemiology trends @
Chronic Kidney Disease Epidemiological Insights
Chronic Kidney Disease Treatment Market
There are various types of drugs in the chronic kidney disease market. Although available medications cannot cure CKD, they can treat problems and halt future kidney damage. DelveInsight's chronic kidney disease market projection focuses on pharmacological therapy (including all presently utilized off-label medications) recommended for chronic kidney disease management and excludes revenue produced by devices and surgical procedures, including dialysis.
The chronic kidney disease drugs market is classified for the study based on drug class, such as erythropoietin stimulating agents (ESA), angiotensin-converting enzyme inhibitorsangiotensin-converting enzyme inhibitors, and angiotensin receptor blockers (ACE-I and ARBs), antidiabetics, secondary hyperparathyroidism treatment (SHPT), and urate-lowering therapies. There are also approved therapies for chronic kidney disease treatment, such as
KERENDIA, INVOKANA, JYNARQUE, and FARXIGA.
According to DelveInsight's analysis, antidiabetics and antihypertensives are the most widely utilized among the top prescribed pharmaceuticals. Given the health risks associated with renal dysfunction, DelveInsight analysts developed a comprehensive understanding of chronic kidney disease and its etiologies, defining the breadth of the therapeutic paradigm. The chronic kidney disease treatment market is classified into three segments: diabetic kidney disease (DKD), polycystic kidney disease (PKD), and hypertension induced kidney disease.
To know more about chronic kidney disease treatment guidelines, visit @
Chronic Kidney Disease Therapies and Key Companies
Renal Autologous Cell Therapy (REACT): ProKidney
KBP-5074: KBP Biosciences
KT-301: Kibow Pharma
Learn more about the FDA-approved drugs for chronic kidney disease @
Drugs for Chronic Kidney Disease Treatment
Chronic Kidney Disease Market Dynamics
The dynamics of the chronic kidney disease market are expected to change in the coming years. The emerging treatment pipeline is
robustly humongous, attributing to novel MoAs. Moreover, the
rising data on chronic kidney disease and its risk factors is expected to add significantly to the patient pool. Furthermore, the current therapy paradigm includes
FARXIGA (SGLT2 inhibitor), which is utilized for diabetic and non-diabetic chronic kidney disease patients. In the US, FARXIGA had a market size of
USD 111 million in 2021 and is anticipated to reach
USD 559 million as its peak revenue. Top SGLT2 players have been competing for lucrative approvals in recent years. The chronic kidney disease market may see another approval with
Boehringer Ingelheim Pharmaceuticals, Inc by 2023. Empagliflozin has achieved landmark results in chronic kidney disease studies and would be a contender to FARXIGA because the findings could pave the road for a catch-up approval. Farxiga's sales have increased considerably as the label has expanded, but Jardiance is not far behind. According to the model, the therapy will produce a chronic kidney disease market size of
USD 9 million by its launch year (2023), and this chronic kidney disease market size is predicted to grow to
USD 772 million by 2032.
However, several factors may impede the growth of the chronic kidney disease market, such as the
undiagnosed, unreported cases, and unawareness about the disease may also impact future chronic kidney disease market growth. On the contrary, there are significant factors that may contribute to the growth in the market, as chronic kidney disease is associated with major complications, including
anemia, hyperparathyroidism, and metabolic acidosis. Moreover, there is a scope for
branded pharmacologic treatment with good safety and efficacy data and broader range coverage like impulse control.
Scope of the
Market Report
Therapeutic Assessment: Chronic Kidney Disease current marketed and emerging therapies
Market Dynamics: Attribute Analysis of Emerging Chronic Kidney Disease Drugs
Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
Unmet Needs, KOL's Views, Analyst's Views, Chronic Kidney Disease Market Access and Reimbursement
Discover more about chronic kidney disease drugs in development @
Chronic Kidney Disease Clinical Trials
Table of Contents
Related Reports
Chronic Kidney Disease Epidemiology Forecast
Chronic Kidney Disease Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted chronic kidney disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Chronic Kidney Disease Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key chronic kidney disease companies, including
Moderate and Severe Chronic Kidney Disease Market
Moderate and Severe Chronic Kidney Disease Market Insights, Epidemiology, and Market Forecast
– 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key moderate and severe chronic kidney disease companies, including
Moderate and Severe Chronic Kidney Disease Pipeline
Moderate and Severe Chronic Kidney Disease Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key moderate and severe chronic kidney disease companies, including
Anemia In Chronic Kidney Disease Market Insights, Epidemiology, and Market Forecast
– 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key anemia in chronic kidney disease companies, including
Anemia In Chronic Kidney Disease Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key anemia in chronic kidney disease companies, including
Other Trending Reports
Tay-sachs Disease Or Gm2 Gangliosidosis Market | Onycholysis Market | Diagnostic Imaging Equipment Market | Chemotherapy-induced Peripheral Neuropathy Market | Global Electrophysiology Devices Market | Anaphylaxis Market | Atherectomy Devices Market | Helicobacter Pylori Infections Market | Ophthalmic Imaging Equipment Market | Androgenetic Alopecia Market | Allergic Rhinitis Market | Chronic Inflammatory Demyelinating Polyneuropathy Market | Chronic Inflammatory Demyelinating Polyneuropathy Market | Colorectal Cancer Crc Market | Opioid Induced Constipation Market | Vertigo Market | Bone Anchored Hearing Systems Market | Wound Closure Devices Market | Hip Replacement Devices Market | Hemodynamic Monitoring Systems Market
| Egfr Non-small Cell Lung Cancer Market | Helicobacter Pylori Infection Market | Hyperkalemia Market | Polycythemia Market Neurostimulation Devices Market | Carpal Tunnel Syndrome Market | Ventilator Market | Cerebral Aneurysm Market | Alpha Antitrypsin Market | Binge Eating Disorder Market | Bunion Market | Concussions Market Size | Exocrine Pancreatic Insufficiency Market | Healthcare Due Diligence Services | Minimal Residual Disease Market | Hypertrophic Scar Market | Lung Fibrosis Market | Anterior Uveitis Market | 22q11.2 deletion syndrome Market | X-Linked Retinitis Pigmentosa (XLRP) Market | Acute Radiation Syndrome Market | Alpha-1 Protease Inhibitor Deficiency Market | Androgenetic Alopecia Market | Hyperlipidemia Market | Cardiotoxicity Market | Hypertrophic Cardiomyopathy Market | Fatty Acid Oxidation Disorders (FAODs) Market | Androgen Insensitivity Syndrome Market | Emphysema Market | Canaloplasty Market | Dravet Syndrome Market | Celiac Disease Market | Chlamydia Infections Market | Syphilis Market | Renal Tubular Acidosis Market | Palmoplantar Pustulosis (PPP) Market | Aplastic Anemia Market | Bacterial Pneumonia Market | B cell Chronic Lymphocytic Leukemia Market | B cell Lymphomas Market | Behcets Disease Market Neoantigen-based Personalized Cancer therapeutic Vaccines Competitive Landscape and Market Forecast—by 2035 | Glioblastoma Market
Related Healthcare Services
Healthcare Consulting
Healthcare Competitive Intelligence Services
Healthcare Asset Prioritization Services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
.
Connect with us on LinkedIn
|Facebook|Twitter
Contact Us
Shruti Thakur
[email protected]
+1(919)321-6187
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.